Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ulrich Germing

Showing results (211-220 of 339) with videos related to

Pageof 34
Sort By:
Blood|August 10, 2010
Next-generation sequencing of the TET2 gene in 355 MDS and CMML patients reveals low-abundance mutant clones with early origins, but indicates no definite prognostic valueAlexander E Smith, Azim M Mohamedali, Austin Kulasekararaj, et al.
Blood|August 30, 2007
New insights into the prognostic impact of the karyotype in MDS and correlation with subtypes: evidence from a core dataset of 2124 patientsDetlef Haase, Ulrich Germing, Julie Schanz, et al.
Haematologica|October 8, 2008
Diagnosis and classification of myelodysplastic syndrome: International Working Group on Morphology of myelodysplastic syndrome (IWGM-MDS) consensus proposals for the definition and enumeration of myeloblasts and ring sideroblastsGhulam J Mufti, John M Bennett, Jean Goasguen, et al.
Blood|August 5, 2015
Prognostic value of circulating Bcl-2/IgH levels in patients with follicular lymphoma receiving first-line immunochemotherapyFabian Zohren, Ingmar Bruns, Sabrina Pechtel, et al.
British Journal of Haematology|October 8, 2016
Mammalian-target of rapamycin inhibition with temsirolimus in myelodysplastic syndromes (MDS) patients is associated with considerable toxicity: results of the temsirolimus pilot trial by the German MDS Study Group (D-MDS)Martin Wermke, Claudia Schuster, Florian Nolte, et al.
Haematologica|November 8, 2011
A multicenter phase II trial of decitabine as first-line treatment for older patients with acute myeloid leukemia judged unfit for induction chemotherapyMichael Lübbert, Björn H Rüter, Rainer Claus, et al.
Haematologica|August 5, 2018
Normal and pathological erythropoiesis in adults: from gene regulation to targeted treatment conceptsPeter Valent, Guntram Büsche, Igor Theurl, et al.
Leukemia Research|November 19, 2020
Outcome of lower-risk myelodysplastic syndrome with ring sideroblasts (MDS-RS) after failure of erythropoiesis- stimulating agentsSophie Park, Jean-François Hamel, Andrea Toma, et al.
Annals of Hematology|September 6, 2025
Comparison of prognostication by IPSS-M, IPSS-R and AIPSS-MDS in the context of limited availability of molecular data in daily clinical practiceFelicitas Schulz, Carolin Kellersmann, Beate Betz, et al.
Stem Cells (Dayton, Ohio)|May 20, 2021
Acute myeloid leukemia-induced functional inhibition of healthy CD34+ hematopoietic stem and progenitor cellsPaul Jäger, Stefanie Geyh, Sören Twarock, et al.
Pageof 34

Showing results (211-220 of 339) with videos related to

Sort By:
Pageof 34
Blood|August 10, 2010
Next-generation sequencing of the TET2 gene in 355 MDS and CMML patients reveals low-abundance mutant clones with early origins, but indicates no definite prognostic valueAlexander E Smith, Azim M Mohamedali, Austin Kulasekararaj, et al.
Blood|August 30, 2007
New insights into the prognostic impact of the karyotype in MDS and correlation with subtypes: evidence from a core dataset of 2124 patientsDetlef Haase, Ulrich Germing, Julie Schanz, et al.
Haematologica|October 8, 2008
Diagnosis and classification of myelodysplastic syndrome: International Working Group on Morphology of myelodysplastic syndrome (IWGM-MDS) consensus proposals for the definition and enumeration of myeloblasts and ring sideroblastsGhulam J Mufti, John M Bennett, Jean Goasguen, et al.
Blood|August 5, 2015
Prognostic value of circulating Bcl-2/IgH levels in patients with follicular lymphoma receiving first-line immunochemotherapyFabian Zohren, Ingmar Bruns, Sabrina Pechtel, et al.
British Journal of Haematology|October 8, 2016
Mammalian-target of rapamycin inhibition with temsirolimus in myelodysplastic syndromes (MDS) patients is associated with considerable toxicity: results of the temsirolimus pilot trial by the German MDS Study Group (D-MDS)Martin Wermke, Claudia Schuster, Florian Nolte, et al.
Haematologica|November 8, 2011
A multicenter phase II trial of decitabine as first-line treatment for older patients with acute myeloid leukemia judged unfit for induction chemotherapyMichael Lübbert, Björn H Rüter, Rainer Claus, et al.
Haematologica|August 5, 2018
Normal and pathological erythropoiesis in adults: from gene regulation to targeted treatment conceptsPeter Valent, Guntram Büsche, Igor Theurl, et al.
Leukemia Research|November 19, 2020
Outcome of lower-risk myelodysplastic syndrome with ring sideroblasts (MDS-RS) after failure of erythropoiesis- stimulating agentsSophie Park, Jean-François Hamel, Andrea Toma, et al.
Annals of Hematology|September 6, 2025
Comparison of prognostication by IPSS-M, IPSS-R and AIPSS-MDS in the context of limited availability of molecular data in daily clinical practiceFelicitas Schulz, Carolin Kellersmann, Beate Betz, et al.
Stem Cells (Dayton, Ohio)|May 20, 2021
Acute myeloid leukemia-induced functional inhibition of healthy CD34+ hematopoietic stem and progenitor cellsPaul Jäger, Stefanie Geyh, Sören Twarock, et al.
Pageof 34